{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=5", "query": { "intervention": "HER2-targeted Therapy", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 110, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:22:04.830Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04329065", "title": "Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8" ], "interventions": [ { "name": "pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-04-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04329065" }, { "nct_id": "NCT05079360", "title": "Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Sabizabulin", "type": "DRUG" }, { "name": "Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veru Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 0, "start_date": "2023-03-15", "completion_date": "2024-05-26", "has_results": false, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 22 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05079360" }, { "nct_id": "NCT02751528", "title": "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ETBX-021", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantBioScience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-03-04", "completion_date": "2018-08-16", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 2, "location_summary": "El Segundo, California • Sioux Falls, South Dakota", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751528" }, { "nct_id": "NCT07869836", "title": "BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer", "Metastatic Urothelial Cancer", "Bladder Cancer", "Bladder Cancer (BC)", "Bladder (Urothelial, Transitional Cell) Cancer", "Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable", "Bladder Ca", "Bladder Cancer Recurrent", "Bladder Cancer Stage IV", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent", "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "T-Bren, Dose level 1", "type": "DRUG" }, { "name": "T-bren, Dose level 2", "type": "DRUG" }, { "name": "Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2026-09", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 1, "location_summary": "Macon, Georgia", "locations": [ { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869836" }, { "nct_id": "NCT00627627", "title": "A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "IPI-504", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 56, "start_date": "2008-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-02-03", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627627" }, { "nct_id": "NCT03493854", "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab IV", "type": "DRUG" }, { "name": "FDC of Pertuzumab and Trastuzumab SC", "type": "DRUG" }, { "name": "Trastuzumab IV", "type": "DRUG" }, { "name": "Trastuzumab SC", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Post-operative Radiotherapy", "type": "RADIATION" }, { "name": "Hormone Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2018-06-14", "completion_date": "2023-06-02", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 4, "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Rockville", "state": "Maryland" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Lakewood", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493854" }, { "nct_id": "NCT04025216", "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Triple Negative Breast Cancer", "Multiple Myeloma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "CART-TnMUC1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-10-10", "completion_date": "2022-12-02", "has_results": false, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025216" }, { "nct_id": "NCT02693535", "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Advanced Solid Tumors" ], "interventions": [ { "name": "Sunitinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Olaparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Abemaciclib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Dabrafenib plus Trametinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4200, "start_date": "2016-03-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 174, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693535" }, { "nct_id": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Lumpectomy", "type": "PROCEDURE" }, { "name": "Mastectomy", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2175, "start_date": "2020-03-13", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 999, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04266249" }, { "nct_id": "NCT02774421", "title": "Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Posterior Fossa Ependymoma (PFEPN)" ], "interventions": [ { "name": "Trastuzumab after SubQ GM-CSF", "type": "DRUG" }, { "name": "Trastuzumab in combination with SubQ GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 10, "start_date": "2017-06-12", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-14T00:22:04.830Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02774421" } ] }